Arizona Start-Up Receives 510(k) Clearance for Mobile Ultrasound
Emagine Solutions Technology cleared to market VistaScan platform.
Courtney Williams, Emagine Solutions Technology co-founder and chief executive officer, with VistaScan system. Courtesy: Emagine Solutions Technology
Today, Arizona-based medical software device company Emagine Solutions Technology received 510(k) clearance from the U.S. Food and Drug Administration for its VistaScan mobile ultrasound platform that turns a provider’s cell phone or tablet into a portable solution.
“The velocity and complexity of modern medicine is becoming overwhelming, and putting the power of ultrasound into the pockets of clinicians so they can use it for real time diagnosis right at the bedside is liberating and transformative,” said Berndt Schmit, M.D., section chief of emergency radiology at Banner University Medical Center at the University of Arizona and Humanitarian Radiology Development Corps president, in a statement.
According to company information, the platform costs more than 10 times less than a standard ultrasound machine and pairs compatible FDA-cleared ultrasound probes with the VistaScan software application. After downloading the VistaScan app and plugging in one of the three existing probes, clinicians can begin scanning. Through the propriety patent-pending Dynamic Precise Point Measuring System, healthcare providers can use their mobile device’s touchscreen to make precise, pixel-level measurements of an ultrasound image, facilitating diagnostic performance and speed. In addition, providers have several hours of scanning capability without a need to recharge.
Initial applications are expected to be in obstetrics.
“Receiving FDA clearance is excellent validation of our technology and demonstrates the role handheld ultrasound will play in enhancing patient care,” said Courtney Williams, Emagine Solutions Technology co-founder and chief executive officer.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Ultrasound-Guided Thermal Ablation Shows Low Recurrence of Thyroid Carcinoma at Five Years
June 16th 2025In a meta-analysis involving over 2,200 patients with T1NoMo papillary thyroid carcinoma, researchers noted 2 percent recurrence and no cases of lymph node metastasis five years after ultrasound-guided thermal ablation.
